<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001635'>Heart failure</z:hpo> , a syndrome associated with increasing prevalence, high mortality, and frequent hospital admissions, imposes a significant economic burden on western healthcare systems that is expected to further increase in the future due to the ageing population </plain></SENT>
<SENT sid="1" pm="."><plain>Hospitalizations are responsible for the largest part of treatment costs and, thus, the main target for strategies aiming at cost reduction </plain></SENT>
<SENT sid="2" pm="."><plain>Current literature suggests that evidence-based therapy with drugs, devices, and modern disease management programmes improves clinical outcomes of the large population of <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients in a largely cost-effective manner </plain></SENT>
<SENT sid="3" pm="."><plain>However, comprehensive knowledge about the cost of treatment is important to guide clinicians in the responsible allocation of today's limited health-care resources </plain></SENT>
<SENT sid="4" pm="."><plain>This review provides information about the total cost of <z:hpo ids='HP_0001635'>heart failure</z:hpo> and the contribution of different treatment components to the overall costs </plain></SENT>
</text></document>